Diagnosing Frontotemporal Lobar Degeneration
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Observational Study.
- Who it may be relevant to
- Registry conditions: Corticobasal Syndrome, Progressive Supranuclear Palsy, Behavioral Variant Frontotemporal Dementia, Semantic Dementia. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration
Overview
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
Detailed description
The goal of this study is to determine the best diagnostic test for diagnosing frontotemporal lobar degeneration. To accomplish this, the current study will evaluate different tests: brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking abilities, everyday functioning, and brain autopsy. The study team hopes that this information can be used to guide diagnosis and further understanding of mechanism of disease in Frontotemporal Lobar Degeneration and possibly treatment in the future.
Interventions
- Other Observational Study
Primary outcome measures
- Structural and Functional Diffferences between the FTLD groups via MRI of the brain [Time frame: One time visit through study completion of 5 years]
- Differences between the FTLD groups via PET imaging of the brain [Time frame: One time visit through study completion of 5 years]
Eligibility criteria
Inclusion criteria
- Participant must have a reliable study partner who can provide an independent evaluation of functioning.
- Able to read, understand and speak English for neuropsychological testing.
- All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \[18F\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND
- Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28
Exclusion criteria
- Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD
- History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.
- Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Canada · 1 center
- Toronto Western Hospital, University Health Network — Toronto
Identifiers
NCT: NCT02964637 · 14-8398-A